<DOC>
	<DOCNO>NCT02073227</DOCNO>
	<brief_summary>The purpose study assess bioequivalence fix dose combination ( two component combine one tablet ) canagliflozin metformin extend release ( XR ) tablet ( dose 2 X 150 mg/1,000 mg ) respect individual component canagliflozin ( 1 x 300 mg ) metformin XR tablet ( 4 x 500 mg ) healthy fed participant .</brief_summary>
	<brief_title>A Bioequivalence Study Fixed Dose Combination Tablets Canagliflozin Metformin Extended Release ( XR ) With Respect Individual Components</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( physicians participant know identity assign treatment ) , single-center , single-dose , 3-treatment , 3-way crossover ( medication provide participant different sequence ) study canagliflozin ( CANA ) metformin extend release ( MET XR ) combine one tablet , comparison tablet contain individual component . Two Fixed Dose Combinations ( FDCs ) evaluate study ( two type tablet ) . The tablet strength ( 150 mg CANA/1,000 mg MET XR ) compare equal dos individual drug : canagliflozin ( 1 x 300 mg tablet ) metformin XR ( 4 x 500 mg tablet ) . Thus , 3 treatment period study : Treatment A : `` Reference '' treatment individual component administer concurrently ; Treatment B : CANA/MET XR FDC , formulation 1 ; Treatment C : CANA/MET XR FDC , formulation 2 . Approximately 42 healthy adult participant randomly assign 1 3 treatment group , group receive three treatment different sequence ( 3-way crossover ) . The study consist 3 phase : Screening Phase approximately 3 week , Open-Label Treatment Phase consist 3 single-dose Treatment Periods 5 day separate washout period 10 14 day Follow-up Phase occur 7 10 day last study-related procedure Treatment Period 3 . The total duration study 70 day participant .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must sign inform consent document indicate understand purpose study procedure Must body mass index ( BMI ) 18 30 kg/m2 , inclusive Must body weight less 50 kg Must blood pressure 90 140 mmHg inclusive , systolic , high 90 mmHg diastolic screen Must normal renal function evidence kidney damage ( include abnormality blood urine test ) History current clinically significant medical illness Use prescription nonprescription medication ( include vitamin herbal supplement ) History clinically significant allergy , especially know hypersensitivity intolerance drug lactose Known allergy heparin history heparin induce thrombocytopenia Donated blood blood product substantial loss blood within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>